Randomized phase II trial of sulindac for lung cancer chemoprevention

Paul John Limburg, Sumithra J Mandrekar, Marie Christine Aubry, Katie L Allen Ziegler, Jun Zhang, Joanne E. Yi, Michael Henry, Henry D. Tazelaar, Stephen Lam, Annette McWilliams, David Eric Midthun, Eric Edell, Otis B. Rickman, Peter Mazzone, Melvyn Tockman, John F. Beamis, Carla Lamb, Michael Simoff, Charles Lawrence Loprinzi, Eva Szabo & 1 others James Jett

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Sulindac represents a promising candidate agent for lung cancer chemoprevention, but clinical trial data have not been previously reported. We conducted a randomized, phase II chemoprevention trial involving current or former cigarette smokers (≥30 pack-years) utilizing the multi-center, inter-disciplinary infrastructure of the Cancer Prevention Network (CPN). Methods: At least 1 bronchial dysplastic lesion identified by fluorescence bronchoscopy was required for randomization. Intervention assignments were sulindac 150. mg bid or an identical placebo bid for 6 months. Trial endpoints included changes in histologic grade of dysplasia (per-participant as primary endpoint and per lesion as secondary endpoint), number of dysplastic lesions (per-participant), and Ki67 labeling index. Results: Slower than anticipated recruitment led to trial closure after randomizing participants (n=31 and n=30 in the sulindac and placebo arms, respectively). Pre- and post-intervention fluorescence bronchoscopy data were available for 53/61 (87%) randomized, eligible participants. The median (range) of dysplastic lesions at baseline was 2 (1-12) in the sulindac arm and 2 (1-7) in the placebo arm. Change in dysplasia was categorized as regression:stable:progression for 15:3:8 (58%:12%:31%) subjects in the sulindac arm and 15:2:10 (56%:7%:37%) subjects in the placebo arm; these distributions were not statistically different (p=0.85). Median Ki67 expression (% cells stained positive) was significantly reduced in both the placebo (30 versus 5; p=0.0005) and sulindac (30 versus 10; p=0.0003) arms, but the difference between arms was not statistically significant (p=0.92). Conclusions: Data from this multi-center, phase II squamous cell lung cancer chemoprevention trial do not demonstrate sufficient benefits from sulindac 150. mg bid for 6 months to warrant additional phase III testing. Investigation of pathway-focused agents is necessary for lung cancer chemoprevention.

Original languageEnglish (US)
Pages (from-to)254-261
Number of pages8
JournalLung Cancer
Volume79
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Sulindac
Chemoprevention
Lung Neoplasms
Placebos
Bronchoscopy
Fluorescence
Squamous Cell Neoplasms
Random Allocation
Tobacco Products
Clinical Trials

Keywords

  • Chemoprevention
  • Lung cancer
  • NSAIDs
  • Phase II clinical trial
  • Sulindac

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Randomized phase II trial of sulindac for lung cancer chemoprevention. / Limburg, Paul John; Mandrekar, Sumithra J; Aubry, Marie Christine; Ziegler, Katie L Allen; Zhang, Jun; Yi, Joanne E.; Henry, Michael; Tazelaar, Henry D.; Lam, Stephen; McWilliams, Annette; Midthun, David Eric; Edell, Eric; Rickman, Otis B.; Mazzone, Peter; Tockman, Melvyn; Beamis, John F.; Lamb, Carla; Simoff, Michael; Loprinzi, Charles Lawrence; Szabo, Eva; Jett, James.

In: Lung Cancer, Vol. 79, No. 3, 03.2013, p. 254-261.

Research output: Contribution to journalArticle

Limburg, PJ, Mandrekar, SJ, Aubry, MC, Ziegler, KLA, Zhang, J, Yi, JE, Henry, M, Tazelaar, HD, Lam, S, McWilliams, A, Midthun, DE, Edell, E, Rickman, OB, Mazzone, P, Tockman, M, Beamis, JF, Lamb, C, Simoff, M, Loprinzi, CL, Szabo, E & Jett, J 2013, 'Randomized phase II trial of sulindac for lung cancer chemoprevention', Lung Cancer, vol. 79, no. 3, pp. 254-261. https://doi.org/10.1016/j.lungcan.2012.11.011
Limburg, Paul John ; Mandrekar, Sumithra J ; Aubry, Marie Christine ; Ziegler, Katie L Allen ; Zhang, Jun ; Yi, Joanne E. ; Henry, Michael ; Tazelaar, Henry D. ; Lam, Stephen ; McWilliams, Annette ; Midthun, David Eric ; Edell, Eric ; Rickman, Otis B. ; Mazzone, Peter ; Tockman, Melvyn ; Beamis, John F. ; Lamb, Carla ; Simoff, Michael ; Loprinzi, Charles Lawrence ; Szabo, Eva ; Jett, James. / Randomized phase II trial of sulindac for lung cancer chemoprevention. In: Lung Cancer. 2013 ; Vol. 79, No. 3. pp. 254-261.
@article{fd2175a7f7434dc384f72b81521d43bc,
title = "Randomized phase II trial of sulindac for lung cancer chemoprevention",
abstract = "Introduction: Sulindac represents a promising candidate agent for lung cancer chemoprevention, but clinical trial data have not been previously reported. We conducted a randomized, phase II chemoprevention trial involving current or former cigarette smokers (≥30 pack-years) utilizing the multi-center, inter-disciplinary infrastructure of the Cancer Prevention Network (CPN). Methods: At least 1 bronchial dysplastic lesion identified by fluorescence bronchoscopy was required for randomization. Intervention assignments were sulindac 150. mg bid or an identical placebo bid for 6 months. Trial endpoints included changes in histologic grade of dysplasia (per-participant as primary endpoint and per lesion as secondary endpoint), number of dysplastic lesions (per-participant), and Ki67 labeling index. Results: Slower than anticipated recruitment led to trial closure after randomizing participants (n=31 and n=30 in the sulindac and placebo arms, respectively). Pre- and post-intervention fluorescence bronchoscopy data were available for 53/61 (87{\%}) randomized, eligible participants. The median (range) of dysplastic lesions at baseline was 2 (1-12) in the sulindac arm and 2 (1-7) in the placebo arm. Change in dysplasia was categorized as regression:stable:progression for 15:3:8 (58{\%}:12{\%}:31{\%}) subjects in the sulindac arm and 15:2:10 (56{\%}:7{\%}:37{\%}) subjects in the placebo arm; these distributions were not statistically different (p=0.85). Median Ki67 expression ({\%} cells stained positive) was significantly reduced in both the placebo (30 versus 5; p=0.0005) and sulindac (30 versus 10; p=0.0003) arms, but the difference between arms was not statistically significant (p=0.92). Conclusions: Data from this multi-center, phase II squamous cell lung cancer chemoprevention trial do not demonstrate sufficient benefits from sulindac 150. mg bid for 6 months to warrant additional phase III testing. Investigation of pathway-focused agents is necessary for lung cancer chemoprevention.",
keywords = "Chemoprevention, Lung cancer, NSAIDs, Phase II clinical trial, Sulindac",
author = "Limburg, {Paul John} and Mandrekar, {Sumithra J} and Aubry, {Marie Christine} and Ziegler, {Katie L Allen} and Jun Zhang and Yi, {Joanne E.} and Michael Henry and Tazelaar, {Henry D.} and Stephen Lam and Annette McWilliams and Midthun, {David Eric} and Eric Edell and Rickman, {Otis B.} and Peter Mazzone and Melvyn Tockman and Beamis, {John F.} and Carla Lamb and Michael Simoff and Loprinzi, {Charles Lawrence} and Eva Szabo and James Jett",
year = "2013",
month = "3",
doi = "10.1016/j.lungcan.2012.11.011",
language = "English (US)",
volume = "79",
pages = "254--261",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Randomized phase II trial of sulindac for lung cancer chemoprevention

AU - Limburg, Paul John

AU - Mandrekar, Sumithra J

AU - Aubry, Marie Christine

AU - Ziegler, Katie L Allen

AU - Zhang, Jun

AU - Yi, Joanne E.

AU - Henry, Michael

AU - Tazelaar, Henry D.

AU - Lam, Stephen

AU - McWilliams, Annette

AU - Midthun, David Eric

AU - Edell, Eric

AU - Rickman, Otis B.

AU - Mazzone, Peter

AU - Tockman, Melvyn

AU - Beamis, John F.

AU - Lamb, Carla

AU - Simoff, Michael

AU - Loprinzi, Charles Lawrence

AU - Szabo, Eva

AU - Jett, James

PY - 2013/3

Y1 - 2013/3

N2 - Introduction: Sulindac represents a promising candidate agent for lung cancer chemoprevention, but clinical trial data have not been previously reported. We conducted a randomized, phase II chemoprevention trial involving current or former cigarette smokers (≥30 pack-years) utilizing the multi-center, inter-disciplinary infrastructure of the Cancer Prevention Network (CPN). Methods: At least 1 bronchial dysplastic lesion identified by fluorescence bronchoscopy was required for randomization. Intervention assignments were sulindac 150. mg bid or an identical placebo bid for 6 months. Trial endpoints included changes in histologic grade of dysplasia (per-participant as primary endpoint and per lesion as secondary endpoint), number of dysplastic lesions (per-participant), and Ki67 labeling index. Results: Slower than anticipated recruitment led to trial closure after randomizing participants (n=31 and n=30 in the sulindac and placebo arms, respectively). Pre- and post-intervention fluorescence bronchoscopy data were available for 53/61 (87%) randomized, eligible participants. The median (range) of dysplastic lesions at baseline was 2 (1-12) in the sulindac arm and 2 (1-7) in the placebo arm. Change in dysplasia was categorized as regression:stable:progression for 15:3:8 (58%:12%:31%) subjects in the sulindac arm and 15:2:10 (56%:7%:37%) subjects in the placebo arm; these distributions were not statistically different (p=0.85). Median Ki67 expression (% cells stained positive) was significantly reduced in both the placebo (30 versus 5; p=0.0005) and sulindac (30 versus 10; p=0.0003) arms, but the difference between arms was not statistically significant (p=0.92). Conclusions: Data from this multi-center, phase II squamous cell lung cancer chemoprevention trial do not demonstrate sufficient benefits from sulindac 150. mg bid for 6 months to warrant additional phase III testing. Investigation of pathway-focused agents is necessary for lung cancer chemoprevention.

AB - Introduction: Sulindac represents a promising candidate agent for lung cancer chemoprevention, but clinical trial data have not been previously reported. We conducted a randomized, phase II chemoprevention trial involving current or former cigarette smokers (≥30 pack-years) utilizing the multi-center, inter-disciplinary infrastructure of the Cancer Prevention Network (CPN). Methods: At least 1 bronchial dysplastic lesion identified by fluorescence bronchoscopy was required for randomization. Intervention assignments were sulindac 150. mg bid or an identical placebo bid for 6 months. Trial endpoints included changes in histologic grade of dysplasia (per-participant as primary endpoint and per lesion as secondary endpoint), number of dysplastic lesions (per-participant), and Ki67 labeling index. Results: Slower than anticipated recruitment led to trial closure after randomizing participants (n=31 and n=30 in the sulindac and placebo arms, respectively). Pre- and post-intervention fluorescence bronchoscopy data were available for 53/61 (87%) randomized, eligible participants. The median (range) of dysplastic lesions at baseline was 2 (1-12) in the sulindac arm and 2 (1-7) in the placebo arm. Change in dysplasia was categorized as regression:stable:progression for 15:3:8 (58%:12%:31%) subjects in the sulindac arm and 15:2:10 (56%:7%:37%) subjects in the placebo arm; these distributions were not statistically different (p=0.85). Median Ki67 expression (% cells stained positive) was significantly reduced in both the placebo (30 versus 5; p=0.0005) and sulindac (30 versus 10; p=0.0003) arms, but the difference between arms was not statistically significant (p=0.92). Conclusions: Data from this multi-center, phase II squamous cell lung cancer chemoprevention trial do not demonstrate sufficient benefits from sulindac 150. mg bid for 6 months to warrant additional phase III testing. Investigation of pathway-focused agents is necessary for lung cancer chemoprevention.

KW - Chemoprevention

KW - Lung cancer

KW - NSAIDs

KW - Phase II clinical trial

KW - Sulindac

UR - http://www.scopus.com/inward/record.url?scp=84873199055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873199055&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2012.11.011

DO - 10.1016/j.lungcan.2012.11.011

M3 - Article

VL - 79

SP - 254

EP - 261

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -